Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Next Previous
Trial Profile

Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Ulevostinag (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Cutaneous T-cell lymphoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Liver cancer; Liver metastases; Lymphoma; Male breast cancer; Mouth neoplasm; Oropharyngeal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 22 Apr 2022 Status changed from active, no longer recruiting to completed.
    • 04 Mar 2022 Planned End Date changed from 20 Oct 2022 to 14 Apr 2022.
    • 04 Mar 2022 Planned primary completion date changed from 20 Oct 2022 to 14 Apr 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top